AstraZeneca announced the launch of AstraZeneca Direct, a new direct-to-consumer (DTC) online platform designed to provide eligible patients with a simple and convenient way to access their prescribed medications at a transparent cash price, delivered directly to their homes.

The platform is being introduced to expand access to treatments for people living with chronic conditions such as asthma, diabetes, heart failure, and chronic kidney disease, as well as for individuals seeking flu protection.

Beginning October 1, 2025, patients with prescriptions for AIRSUPRA (albuterol/budesonide)or FARXIGA (dapagliflozin) will be able to purchase their medicines through AstraZeneca Direct at up to 70 per cent off the list price. In addition, patients will also be able to order FLUMIST (Influenza Vaccine Live, Intranasal) for home delivery.

“AstraZeneca remains deeply committed to improving accessibility and affordability while driving healthcare innovation,” said Joris Silon, U.S. Country President, AstraZeneca. “With AstraZeneca Direct, patients can benefit from transparent pricing and the convenience of home delivery. This program complements our existing patient support services and represents an important step forward in ensuring people receive the medicines they need, when and how they need them.”

AstraZeneca Direct builds on the company’s long-standing U.S. patient support programs, which continue unchanged for eligible patients.